# DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Source: https://welltoldgrants.com/grants/ht942526alsrptda-dow-amyotrophic-lateral-sclerosis-research-program/  
Official notice: https://www.grants.gov/search-results-detail/362196

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 6 awards worth $12.0 million in total. Applications closed on September 30, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526ALSRPTDA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 30, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 6 |
| Total funding | $12.0 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

## Questions people ask

### Is HT942526ALSRPTDA still open?

No. It closed on September 30, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award?

Closed September 30, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $12.0 million in total across about 6 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.